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Background: Carcinoid tumors are slow growing neuroendocrine tumors which can originate from various sites
within the body. A carcinoid tumor originating in the medulla spinalis has not previously been reported in the
literature.
Case report: We report a case of a 33-year-old man, presenting with a five-month history of bilateral lower extremity
pain, as well as paresthesia, and mild weakness in one lateral lower extremity. A lumbar laminectomy of L3 to L5 and
en bloc resection of the tumor was performed. Postoperative histopathology and immunohistochemical analysis of the
tumor were consistent with that of a carcinoid tumor. There were no clinical or radiological signs of tumor recurrence
or metastasis at the patient’s two year postoperative follow-up.
Conclusions: During the differential diagnosis of medulla spinalis tumors, the possibility of a primary carcinoid tumor
originating within the medulla spinalis should be considered. An accurate tumor classification is imperative to ensure
that the most effective course of treatment is pursued.
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Carcinoid tumors (CTs) are neuroendocrine neoplasms
that generally arise from enterochromaffin cells [1]. These
neoplasms are classified as neuroendocrine tumors (NETs)
by the World Health Organization [2]. Malignant CTs
rarely lead to spinal metastases and typically only occur
during the late stages of malignancy [3]. Primary CTs in
the spine are extremely rare and have only been described
in the cervical, sacral [4,5], and coccygeal [6] spine, or the
filum terminale [7,8]. To the best of our knowledge, this is




A 33-year-old man presented with a five-month history
of bilateral radiating pain through the hips, legs and an-
kles. Additionally, he reported numbness, paresthesia and
mild weakness in one lateral lower extremity. A pin-prick
sensation test showed bilateral patchy loss of sensation* Correspondence: bieli@aliyun.com
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unless otherwise stated.and vibration in the legs and feet. The patient did not re-
port bowel or bladder problems. He did not exhibit hyper-
reflexia and was negative for Babinski’s sign.
Magnetic resonance imaging (MRI) revealed a lesion
extending from L3 to L5. T1-weighted MRI of the lum-
bar spine revealed an intradural, extra-medullary, isoin-
tense mass behind the vertebral bodies of L3 to L5 that
was eccentric to the left and showed homogenous en-
hancement with contrast. The vertebral body of L4 ex-
hibited a compressed deformation (Figure 1). Extensive
examination, including gastroscopy, colonoscopy and
computed tomography scans of the abdomen and the
thorax, identified no additional masses in the body.
Operation
A lumbar laminectomy of L3 to L5 was performed. The
tumor was soft with a rich blood supply and closely ad-
hered to the medulla spinalis. There were no signs of
dural invasion and it maintained a clear separating plane.
A total tumor resection was performed.
Follow-up
The patient recovered well from the operation. Lower
extremity pain resolved immediately following surgery,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Pre-operative MR images of the lumbar spine revealed an intradural, extra-medullary, isointense mass behind the vertebral
bodies of L3 to L5. The sagittal T1-weighted image showed the vertebral body of L4 exhibited a compressed deformation (A). The T1-weighted
image showed homogenous enhancement with contrast (B). The axial T1-weighted image showed the vertebral body of L4 exhibited a
compressed deformation (C).
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days. The patient reported symptoms of postoperative
dysuria, which could be attributed to intraoperative injury
to the nerve roots. Dysurea symptoms showed improve-
ment after one week. During the two-year postoperative
follow-up examination the patient exhibited no clin-
ical or MRI radiological signs of tumor recurrence or
metastasis (Figure 2).
Postoperative histopathology of the tumor confirmed a
completely resected solid tumor. The specimen was a
fully encapsulated smooth soft-tissue mass. Standard
hematoxylin and eosin staining revealed sheet-like prolif-
eration of NET cells in a trabecular pattern and no vis-
ible mitoses or necrosis. Additional immunohistochemical
staining demonstrated that the tumor was positive for
synaptophysin, chromogranin (CgA), cytokeratin and
CD56, and negative for S-100 (Figure 2). The Ki-67
labeling index was 2%. These findings are consistent with
the known cellular characteristics of a typical CT.
Discussion
CTs are rare neoplasms that arise from enterochromaffin
cells. The estimated incidence of CT is 0.28 to 0.8 per
100,000 individuals [9]. Spinal metastases of CTs are ex-
tremely rare and occur in fewer than 2% of cases [10,11].
Reports of diagnosis or therapy of primary or metastatic
CTs in the spine are limited, and, as such, it is important
to document these individual cases to understand better
the optimal treatment for patients.
Patients with spinal CTs typically present with symp-
toms that are related to the location of the tumor in the
spine. The most common symptoms are back and ra-
dicular pain, followed by numbness, sphincter dysfunc-
tion and motor weakness as a result of spinal cord and/
or nerve involvement [10].
Imaging plays an important role in the detection and
diagnosis of CT. MRI and computed tomography scans
can be performed to reveal spinal cord lesions. Preopera-
tive T1-weighted MRI of the lumbar spine that revealsisointense and contrast-enhanced intradural masses, simi-
lar to that described in our case, are more likely to result
in a diagnosis of neurinoma or meningioma than CT. In
such cases, the pathologic type of the tumor needs to be
further clarified by postoperative pathology. Neurinoma
and meningioma tumors can be distinguished from CTs
based on characteristic histological and immunohisto-
chemical properties [2].
Total resection of the tumor is the most effective
treatment for patients with spinal CTs. In the present
case, L4 was compressed and a small portion of the lam-
ina and spinous process were surgically resected. A com-
puted tomography scan revealed that most of the L4
vertebral body, pedicle and facet were intact (Figure 3C).
Standing hyperextension, two years after surgery, re-
vealed that no spondylolisthesis was present based on the
Meyerding Grading System. The lumbar spine, therefore,
exhibited good postoperative stability [see Additional
file 1: Figure S1].
Radiotherapy is the best adjuvant option for patients
with CTs. It has been reported to increase disease-free
and overall survival rates in cases of metastatic CT of the
spine. Patients who undergo radiotherapy also achieve
clinical palliation and can considerably improve pain and
neurological symptoms [12]. Some patients can also bene-
fit from chemotherapy [13]; however, there is limited
evidence for chemotherapy and radiotherapy approaches
in the management of primary spinal CT.
Further genetic-based studies are likely to elucidate
the molecular mechanisms leading to CT and may reveal
more effective or individualized therapeutic approaches.
Several studies have found that promoter methylation of
tumor suppressor genes is associated with the suppres-
sion of gene expression and DNA copy number alter-
ations in small intestinal NETs [14,15]. Valentino et al.
reported that co-targeting the PI3K and RAS path-
ways effectively inhibits NET cell proliferation and
stimulates apoptosis [16]. Swarts et al. showed that
gene mutations and reduced expression of multiple
Figure 2 Microphotographs of specimen histology showed
plump round cells with a daisy formation (hematoxylin and
eosin staining, magnification × 400). (A) Microphotographs of
specimen histology showed that the tumor cells were positive
for chromogranin (B), synaptophysin (C), cytokeratin (D), vimentin
(E) and CD56 (F), and negative for S-100 (G), GFAP (H),
pathogenesis related protein (I) and epithelial membrane antigen
(J). These findings confirmed the diagnosis of carcinoid tumor
(immunohistochemical staining, magnification × 200).
Figure 3 T1-weighted postoperative MR images of the lumbar
spine after contrast application showed no tumor recurrence
two years after surgery. Sagittal T1-weighted postoperative MR
images of the lumbar spine (A). Axial T1-weighted postoperative
MR images of the lumbar spine (B, C). MR, magnetic resonance.
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prognoses in pulmonary carcinoid tumors [17]. Plasma
levels of CgA are significantly elevated in CTs and exhibit
high sensitivity and specificity as a biomarker for CT diag-
nosis. CgA can also be used as a tumor development bio-
marker and for evaluating prognosis during clinical
applications [18,19]. Plasma concentrations of tyrosine
kinase-2 (Tie-2) have also been proposed as a specific bio-
marker for NET [20].Follow-up care relying on multiple imaging approaches
is important for the detection of tumor recurrence and
metastasis. Recurrence monitoring should include postop-
erative assessment of 5-hydroxyindoleacetic acid levels in
24-hour urine and plasma CgA levels [21].
Conclusions
Although rare, primary CTs of the medulla spinalis
should be considered in the differential diagnoses of me-
dulla spinalis tumors. Accurate classifications of tumor
type will lead to more effective tumor therapy. Surgery
is currently the most effective treatment technique for
spinal CTs. The use of radiotherapy and chemother-
apy for patients should be considered on an individ-
ual basis.
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